Filing summary: FY2012 Form 10-K
Entity and period: The supplied filing is for Mast Therapeutics, Inc. (then formerly ADVENTRX Pharmaceuticals, Inc.), not Savara Inc. It covers the fiscal year ended December 31, 2012; it is not a standalone fourth-quarter filing. The company changed its name to Mast Therapeutics in March 2013.
Business context and reporting period
Mast was a development-stage biopharmaceutical company with no marketed products or significant operating revenue. Its resources were focused principally on MST-188, a purified poloxamer 188 candidate being developed for sickle cell disease and other conditions involving impaired microcirculation. The pivotal EPIC Phase 3 study in sickle cell disease began in January 2013, after the fiscal year-end.
Financial performance and liquidity
| Metric | FY2012 | FY2011 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $8.1 million | $5.8 million |
| Selling, general and administrative expense | $7.5 million | $7.2 million |
| Operating loss | $15.6 million | $13.4 million |
| Net loss | $15.6 million | $13.3 million |
| Basic and diluted loss per share | $0.33 | $0.47 |
| Net cash used in operating activities | $13.9 million | $13.5 million |
Product gross margin and operating margins are not meaningful because the company reported no revenue. Fourth-quarter 2012 revenue was $0; net loss was $4.0 million, compared with $2.4 million in fourth-quarter 2011.
At December 31, 2012, cash, cash equivalents and short-term investments totaled $36.5 million, down from $50.7 million a year earlier. Net working capital was $34.6 million; total assets were $47.0 million, total liabilities $5.2 million, and stockholders’ equity $41.8 million. The balance sheet showed no conventional borrowings; management said additional financing would be needed to support planned development beyond the near term.
FY2012 investing cash outflow was $7.2 million, largely reflecting investment purchases and maturities; financing cash flow was approximately zero. The company raised $36.6 million net through equity financings in 2011 and conducted no capital-raising transaction in 2012. Accumulated development-stage deficit was $184.9 million at year-end.
Material changes versus the prior comparable period
- R&D expense rose 40.5% to $8.1 million, primarily with MST-188 manufacturing, clinical planning, consulting and staffing costs as the company prepared for EPIC.
- SG&A increased 4.6% to $7.5 million; higher personnel and share-based compensation costs were partly offset by reduced consulting and legal expenses as work on other programs wound down.
- Net loss increased to $15.6 million from $13.3 million, while loss per share narrowed to $0.33 from $0.47, reflecting the larger weighted-average share count after 2011 equity offerings.
- The company discontinued independent development of ANX-514 in 2012 and Exelbine in 2011, and was pursuing potential partnering or licensing options for both. It recorded a $0.4 million impairment on ANX-514-related equipment in 2012.
- In December 2012, Mast repurchased 1,454,079 SynthRx-related shares for $1,454 under a merger-agreement repurchase right. Further milestone shares may be issued if MST-188 development advances.
Outlook, risks, contingencies and unusual items
- Management expected available cash and investments to fund operations for at least 12 months from the filing’s outlook, but cautioned that this estimate depended on assumptions. It expected significant, increasing losses and R&D expense to rise substantially in 2013.
- Management expected EPIC enrollment to finish in 2015. Estimated external clinical-study costs were $15–18 million for EPIC, about $2 million for the TQT study, and about $2 million for a planned acute limb ischemia Phase 2 study. The latter was expected to start in late 2013 or early 2014, subject partly to FDA input.
- Development in trauma-related shock and other additional indications depended on U.S. government or other third-party funding; government funding was uncertain. The company also planned to seek partners for development outside the U.S. and potentially for larger arterial-disease indications.
- Key risks include dependence on a single lead candidate and its clinical and regulatory success; need for further capital and possible dilution; and reliance on a small number of third-party manufacturers, with no planned backup suppliers. The filing also describes potential supply interruptions, enrollment and trial delays, competition, reimbursement uncertainty, and risks to NYSE MKT listing compliance.
- Prior sickle-cell Phase 3 results showed an 8-hour reduction in crisis duration that did not meet statistical significance in the overall intent-to-treat population (p=0.072); a favorable result in patients under 16 was a post hoc analysis. These findings do not establish EPIC’s outcome.
- A $0.4 million accrual related to a disputed ANX-514 manufacturer payment demand was recorded; the company said the dispute’s outcome was uncertain. No material pending litigation was reported. No impairment was identified for goodwill or acquired in-process R&D in the year-end assessment.
Most important facts for investors to verify
- Confirm the issuer identity: the provided 10-K is Mast Therapeutics, not Savara Inc., and the reporting period is FY2012 rather than Q4 alone.
- Track EPIC enrollment, safety and eventual results, and review the full data and statistical analyses behind the earlier sickle-cell studies.
- Assess cash burn against the stated runway, planned trial costs and timing and terms of any future financing or collaboration.
- Verify manufacturing capacity, supply agreements and contingency plans for MST-188’s API and finished drug product.
- Review potential dilution from warrants and SynthRx milestone shares, and the status of the disputed $0.4 million manufacturer claim.